Sagent Pharmaceuticals (SGNT) Misses Q1 EPS by 16c

Sagent Pharmaceuticals (NASDAQ: SGNT) reported Q1 EPS of ($0.15), $0.16 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $67.3 million versus the consensus estimate of $74.3 million.

Sagent’s business plan for fiscal 2016 currently anticipates:

• Net revenue for the year to be in the range of $325 to $365 million;
• Adjusted Gross Profit as a percentage of net revenue in the range of 27% to 30%; and
• Operating expenses in the range of $70 to $80 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c